aTyr Pharma (ATYR) Expected to Announce Quarterly Earnings on Thursday

aTyr Pharma (NASDAQ:ATYR) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect aTyr Pharma to post earnings of ($0.18) per share and revenue of $0.02 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:00 PM ET.

aTyr Pharma Trading Up 0.5%

Shares of ATYR opened at $0.96 on Thursday. The company’s fifty day simple moving average is $0.83 and its 200 day simple moving average is $1.47. aTyr Pharma has a 1-year low of $0.64 and a 1-year high of $7.29. The company has a market cap of $94.51 million, a price-to-earnings ratio of -1.16 and a beta of 0.55.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of aTyr Pharma in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, aTyr Pharma presently has a consensus rating of “Hold” and an average price target of $25.67.

Hedge Funds Weigh In On aTyr Pharma

Several large investors have recently modified their holdings of ATYR. Virtu Financial LLC acquired a new stake in shares of aTyr Pharma during the 4th quarter worth about $62,000. ADAR1 Capital Management LLC lifted its position in aTyr Pharma by 35.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after acquiring an additional 13,385 shares during the last quarter. AQR Capital Management LLC acquired a new stake in aTyr Pharma during the fourth quarter worth approximately $603,000. Deutsche Bank AG boosted its holdings in shares of aTyr Pharma by 3,779.5% during the fourth quarter. Deutsche Bank AG now owns 120,341 shares of the company’s stock worth $94,000 after acquiring an additional 117,239 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of aTyr Pharma by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock valued at $1,789,000 after purchasing an additional 105,514 shares during the last quarter. 61.72% of the stock is owned by institutional investors.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.